Recent Updates
Recently added Catalysts
ONCY

VOTING RESULTS exhibit99.htm ONCOLYTICS BIOTECH INC. Annual and Special Meeting of Holders of Common Shares of Oncolytics Biotech Inc. (the "Issuer")

Tuesday, June 2, 2009 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: and Special Meeting of Holders of Biotech Inc. (the "Issuer") Instrument 51-102 - Continuous Disclosure Obligations General Business Outcome of Vote 1. The election of the following nominees as directors of the Issuer for the ensuing year or until their successors are elected

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
REOLYSIN
Phase 3 · Carcinoma, Squamous Cell of the Head and Neck

Full Press Release Details

and Special Meeting of Holders of
Biotech Inc. (the "Issuer")
Instrument 51-102 - Continuous Disclosure Obligations
General Business Outcome of Vote
1. The election of the following nominees as directors of the Issuer for the ensuing year or until their successors are elected or appointed Carried
(a) Bradley G. Thompson
(b) Douglas Ball
(c) Ger Van Amersfoort
(d) William A. Cochrane
(e) Jim Dinning
(f) Ed Levy
(g) J. Mark Lievonen
(h) Robert B. Schultz
(i) Fred A. Stewart
2. The appointment of Ernst & Young LLP, Chartered Accountants, as auditors of the Issuer to hold office until the next annual meeting Carried
Votes by Ballot
Special Business Outcome of Vote Votes For Votes Against
1. The approval of an increase in the number of common shares reserved for issuance pursuant to the stock option plan of the Issuer Carried 5,138,791 1,894,213
ShareAdd on Google
Tags: ONCY Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 2, 2009

Biotech snapshot

Cash runway
$4M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
REOLYSINPhase 3
Carcinoma, Squamous Cell of the Head and Neck →

Catalyst track record

+48%
best trade around ONCY's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ONCY.

See every catalyst's timing & PoA →